Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study

Abstract

Objective To study the prevalence and impact of comorbidities among a cohort of patients with systemic lupus erythematosus (SLE). Methods This study is retrospective, multicenter including 902 Egyptian patients with SLE. Medical records were reviewed for demographic data, clinical characteristics, routine laboratory findings, immunological profile, and medications. Moreover, SLE Disease Activity Index (SLEDAI), and the Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index scores were calculated. Results Comorbidities were found in 75.5% of the studied group with hypertension and dyslipidemia as the most frequent comorbidities (43.1% and 40.1%, respectively), followed by sicca features, avascular necrosis, diabetes, osteoporosis and renal failure (11.5%,9%, 9%,8.9%, and 7.1%, respectively). Multivariate regression model showed statistically significant relation between the presence of comorbid condition and each of age ( P = 0.006), disease duration ( P = 0.041), SLEDAI at onset ( P < 0.001), cyclophosphamide intake ( P = 0.001), and cumulative pulse intravenous methylprednisone ( P < 0.001). Also, when adjusted to age and sex, those with multiple comorbid conditions had 18.5 increased odds of mortality compared to those without comorbidities (odds ratio (OR), 95% confidence interval (CI) = 18.5 (6.65–51.69)]. Conclusion Patients with SLE suffer from several comorbidities, with an increasing risk with age, longer disease duration, higher SLEDAI at onset, cyclophosphamide intake and cumulative pulse intravenous methylprednisone. Risk of mortality is exponentiated with multiple comorbidities.

Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study

“…Their mean age was 32.5 ± 9.3 years, and their mean disease duration was 9.11 ± 6.26 years. Details of demographic data and clinical and laboratory features of the studied patients are comparable to those in COMOSLE-Egypt study [ 8 ].…”

“…COMOSLE is a retrospective multicenter study in which medical records of 902 SLE patients were reviewed. Patients were attending rheumatology units in four Egyptian University hospitals and one private rheumatology center [ 8 ]. The study was conducted in accordance with the guidelines of the Declaration of Helsinki and was revised and ethically approved by the Research Ethics Committee of the Faculty of Medicine, Cairo University, with the approval number (N-157–2023).…”

Thrombocytopenia and disease outcomes in a cohort of patients with systemic lupus erythematosus. A post hoc analysis of the COMOSLE‐EGYPT study

“…This study is a post hoc analysis of the COMOSLE‐EGYPT study. COMOSLE‐EGYPT is a multicenter, retrospective cohort study that included patients attending rheumatology units in four university hospitals in Egypt (Cairo, Beni‐Suef, Menia, and Fayoum) in addition to a private center in Fayoum 13 . The study was conducted in accordance with the guidelines of the Declaration of Helsinki.…”